Cortexyme has reached a milestone after enrolling 500 patients with mild to moderate Alzheimer’s disease in its ongoing Phase 2/3 GAIN clinical trial testing the company’s investigational treatment COR388 (atuzaginstat). Enrollment for GAIN (NCT03823404) has been open since the second quarter of 2019, with recruitment ongoing at sites in the U.S. and Europe. Data from an interim analysis — scheduled to occur after 300 patients reach 24 weeks of treatment with COR388 — is expected…
You must be logged in to read/download the full post.
The post GAIN Trial Reaches Milestone With 500 Patients Enrolled appeared first on BioNewsFeeds.